UK regulator cuts late-stage clinical trial approval time to two weeks
Drug Discovery World
OCTOBER 16, 2023
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has revealed plans to reduce the time taken to approve the lowest-risk clinical trials by more than 50%. According to the plans, initial applications for the lowest-risk Phase III and IV trials will be processed by the MHRA within 14 days instead of the statutory 30 days.
Let's personalize your content